US Bancorp DE Has $109,000 Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

US Bancorp DE lessened its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 40.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,358 shares of the company’s stock after selling 922 shares during the quarter. US Bancorp DE’s holdings in PROCEPT BioRobotics were worth $109,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Los Angeles Capital Management LLC increased its position in shares of PROCEPT BioRobotics by 183.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 12,980 shares of the company’s stock worth $1,045,000 after purchasing an additional 8,399 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of PROCEPT BioRobotics by 11.2% during the 4th quarter. Bank of New York Mellon Corp now owns 247,345 shares of the company’s stock worth $19,916,000 after purchasing an additional 24,974 shares during the last quarter. Sentry Investment Management LLC increased its position in shares of PROCEPT BioRobotics by 215.6% during the 4th quarter. Sentry Investment Management LLC now owns 4,718 shares of the company’s stock worth $380,000 after purchasing an additional 3,223 shares during the last quarter. IFP Advisors Inc acquired a new position in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $58,000. Finally, Arcadia Investment Management Corp MI acquired a new position in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $64,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Morgan Stanley lowered their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Truist Financial reaffirmed a “buy” rating and set a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, PROCEPT BioRobotics has a consensus rating of “Moderate Buy” and an average target price of $94.29.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ PRCT opened at $57.62 on Monday. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 12 month low of $45.56 and a 12 month high of $103.81. The stock has a 50 day moving average of $70.07 and a 200-day moving average of $79.05. The company has a market capitalization of $3.16 billion, a P/E ratio of -29.55 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, equities research analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).